GlassScriptPhysician profile
Paul A Wagner
NPI 1609932888
$6,422.69
in general payments reported to CMS, 2019-2025
22 companies · $679 in 2025
The $679 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $293 · 2021: $2,078 · 2022: $1,088 · 2023: $529 · 2024: $975 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,183.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,449.18 | 2019-2025 | Precision7, Precision 7, Total30 |
| Johnson & Johnson Vision Care, INC. | $1,211.04 | 2019-2025 | Acuvue |
| Coopervision INC. | $416.63 | 2020-2024 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Biotissue Holdings INC. | $327.07 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $317.85 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $304.34 | 2022-2024 | Infuse, Alden Scleral Zenlens |
| Allergan, INC. | $209.67 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $179.97 | 2019-2021 | |
| Visioneering Technologies, INC. | $168.91 | 2019 | |
| Sight Sciences, INC. | $149.46 | 2021 | |
| Rxsight INC | $132.90 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Lumenis Be INC | $128.60 | 2023 | Optilight |
| Sun Pharmaceutical Industries INC. | $114.45 | 2024 | |
| Glaukos Corporation | $99.72 | 2025 | Idosetr |
| Abb Con-Cise Optical Group LLC | $48.39 | 2019-2025 | Spectacle Lenses |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $42.57 | 2019 | |
| Synergeyes, INC. | $32.19 | 2019 | |
| Kala Pharmaceuticals, INC. | $20.80 | 2021 | |
| Horizon Therapeutics Plc | $20.01 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $16.05 | 2023 | |
| The Walman Optical Company | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.